Immunotherapy has cemented its place as the fourth pillar of cancer treatment, following surgery, chemotherapy, and radiation. Checkpoint inhibitors and T-cell therapies (like CAR-T) currently dominate this space, but the scientific community and industry consensus are pointing towards a new frontier: **Natural Killer (NK) cell-based treatments**. This next generation of cell therapy is poised...